GEN-MKT-18-7897-A
Oct 29, 2024 | Blogs, Echo® MS+ system, Pharma, QTRAP / Triple Quad, ZenoTOF 7600 system | 0 comments
Read time: 2 minutes
Drug development is a challenging process that requires diverse analytical solutions and the expertise of research scientists.
Within drug discovery confident go/no-go decisions need to be made as quickly as possible. Often, highly sensitive techniques are needed to accurately monitor concentrations of biomarkers, therapeutic candidates, and their metabolites. QA/QC laboratories need consistent performance everyday over many years.
We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.
The guide covers bio/pharmaceutical quantitative assays from discovery to QA/QC, for large and small molecules. Discussing challenges regularly faced by scientists, along with potential solutions.
Download the guide >
The guide includes comprehensive chapters addressing multiple challenges and solutions regularly faced in drug development.
Discovery
Development (Small and large molecules)
Regulatory solutions
QA/QC and lot release
Products
Download the guide here >
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
CE‑SDS remains a cornerstone assay for characterizing fragmentation, aggregation, and product‑related impurities in therapeutic proteins. UV detection has been the long‑standing standard. However, it frequently struggles with baseline noise, limited sensitivity for minor fragments, and subjective integration.
At SCIEX, innovation doesn’t stop at instruments; it extends to how you interact with your LC-MS/MS or CE systems every day. That’s why we’re excited to introduce the SCIEX Now spring 2026 improvements: a set of meaningful enhancements shaped directly by your feedback.
Posted by
You must be logged in to post a comment.
Share this post with your network